Abstract:The pH-sensitive cyclosporine A (CyA) nanoparticles were prepared by the solvent displacement method with enteric dissolved polymer of hydroxypropyl methylcellulose phthalate (HPMCP; including HP50 and HP55). The CyA nanoparticles were analyzed by HPLC for yield and encapsulation efficiency, dynamic light scattering for particle size and transmission electron microscopy (TEM) for morphology. The bioavailability of CyA-HP50 and CyA-HP55 nanoparticle colloids were evaluated in rats, compared with the current available CyA microemulsion (Neoral®). The bioavailability of CyA-HP55 nanoparticle colloids with various suspending agents was also investigated. The results obtained demonstrated that the pH-sensitive CyA nanoparticles with a particle size of 50–60 nm and encapsulation efficiency over 95% could be reproducibly prepared. The bioavailability of CyA-HP50 and CyA-HP55 nanoparticle colloids calculated by the AUC0–72 were 82.3% and 119.6%, similar to the reference of Neoral, while the bioavailability of CyA-HP55 nanoparticle colloids was found to be higher than that of CyA-HP50 nanoparticle colloids. The increase of mean residence time (MRT) and the decrease of elimination constant of the central compartment (K10) for both CyA-HP50 and CyA-HP55 nanoparticle colloids compared with the reference indicated significant sustained release of CyA from the nanoparticles. The effects of the suspending agents on the bioavailability of CyA-HP55 nanoparticles were observed, and the bioavailability decreased as the concentration of suspending agents or the viscosity of the nanoparticle colloids increased.

Pharmacokinetics and Enhanced Oral Bioavailability in Beagle Dogs of Cyclosporine A Encapsulated in Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles

Enhancement of Oral Bioavailability of Cyclosporine A: Comparison of Various Nanoscale Drug-Delivery Systems.

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.

Ph-Sensitive Nanoparticles for Improving the Oral Bioavailability of Cyclosporine A.

Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration

Cyclosporin A-loaded poly(ethylene glycol)-b-poly(d,l-lactic acid) micelles: preparation, in vitro and in vivo characterization and transport mechanism across the intestinal barrier.

Preparation and Evaluation of Poly(Ethylene Glycol)–Poly(Lactide) Micelles As Nanocarriers for Oral Delivery of Cyclosporine A

Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles As Oral Drug Delivery Systems: I. in Vitro Evaluation and Enhanced Oral Bioavailability of the Poorly Water-Soluble Drug Simvastatin

Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A.

[Preparation of Cyclosporine A Ph Sensitive Nanoparticles and Oral Pharmacokinetics in Rats].

Controlled Release of Cyclosporine A Self-Nanoemulsifying Systems from Osmotic Pump Tablets: Near Zero-Order Release and Pharmacokinetics in Dogs

[Relative Bioavailability of Cyclosporine A-loaded Hydroxypropyl Methylcellulose Phthalate Nanoparticles for Oral Administration in Rats].

Two Novel Freeze-Dried Ph-Sensitive Cyclosporine A Nanoparticles: Preparation, in Vitro Drug Release, and in Vivo Absorption Enhancement Effects

Readily Restoring Freeze-Dried Probilosomes As Potential Nanocarriers for Enhancing Oral Delivery of Cyclosporine A

Ocular Delivery of Cyclosporine A Based on Glyceryl Monooleate/poloxamer 407 Liquid Crystalline Nanoparticles: Preparation, Characterization,in Vitrocorneal Penetration and Ocular Irritation

Solid Self-Nanoemulsifying Cyclosporine A Pellets Prepared by Fluid-Bed Coating: Stability and Bioavailability Study

Study on Preparation Conditions for Polylactide Nanoparticles Loaded Cyclosporine A and Its Oral Bioavailability in Rats

Preparation of Cyclosporine A -Loaded Cubic Nanoparticles and Determination of Encapsulation Efficiency

Long-term Studies on the Stability and Oral Bioavailability of Cyclosporine A Nanoparticle Colloid

Enhancing The Bioavailability Of Cyclosporine A Using Solid Dispersion Containing Polyoxyethylene (40) Stearate

Amorphous cyclosporin A nanoparticles for enhanced dermal bioavailability